Abstract
Summary.The increasing availability of factor IX concentrates have extended their use in conditions other than factor IX deficiency and especially in combined acquired deficiencies of vitamin K dependent clotting factors.The occurrence of complications such as post‐transfusion hepatitis type B and thromboembolic episodes have prompted the International Committee on Thrombosis and Hemostasis to constitute a Task Force on the clinical use of factor IX concentrates.The various concentrates available and the basis for their method of preparation are listed. Their use in various pathological conditions other than factor IX deficiency and also the occurrence of complications in such conditions are reviewed.The conclusions and the recommendations on the indications and contraindications formulated by the Task Force on the clinical use of factor IX concentrates as issued following the 1974 Basel Meeting are summarized.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
